Signal12 Inc. is a clinical-stage dry eye company that develops novel therapies to address ophthalmic diseases. Through three Phase 3 clinical studies, our proprietary topical drug, Pro-ocular™ has demonstrated efficacy in rapidly reducing signs and symptoms of dry eye disease (DED). It is the first product for DED to utilize transappendageal delivery (drug delivery via hair follicles or sweat glands in the skin) and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. The company has offices in Greenwich, CT and Boston, MA.

Join Our Mission
We are raising capital to complete Phase 3 trials and bring Pro-ocular™ to market. Invest in a future where dry eye sufferers can enjoy lasting relief and improved vision. 

Contact Neil Edwards, CFO, for more information at nedwards@signal12inc.com.

Clinical Trials

Life Sciences

Therapeutics

Signal12

Signal12's headquarters in Greenwich, United States

Signal12

Org chart

Teams

Offices

Similar companies